Lili Wang

Lili Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TLTianyuan Liu
Tianyuan Liu
HGHuimin Gao
Huimin Gao
YZYueyi Zhang
Yueyi Zhang
SWShan Wang
Shan Wang
MLMeixi Lu
Meixi Lu
DZDongwei Zhang
Dongwei Zhang
Hyperuricemia (HUA) is a kind of metabolic disease with high incidence that still needs new countermeasures. Apigenin has uric-lowering and kidney-protective activities, but how apigenin attenuates HUA and renal injury remains largely unexploited. To this end, an acute HUA mouse model was established by intraperitoneal injection of potassium oxazinate and oral administration with hypoxanthine for 7 consecutive days. Apigenin intervention decreased serum uric acid (UA), creatinine (CRE), blood urea nitrogen (BUN), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor (TNF-α), interleukin-18 (IL-18), liver xanthine oxidase (XOD), and urine protein levels, and increased serum interleukin-10 (IL-10) and urine UA and CRE levels in HUA mice. Moreover, administration of apigenin to HUA mice prevented renal injury, decreased renal glucose transporter 9 (GLUT9) and urate anion transporter 1 (URAT1) levels, and increased renal organic anion transporter 1 (OAT1). These alterations were associated with an inhibition of IL-6, phospho-janus kinase 2 (P-JAK2), phospho-signal transducer, and activator of transcription 3 (P-STAT3), and suppression of cytokine signaling 3 (SOCS3) expression in the kidneys. Additionally, the molecular docking results showed that apigenin had strong binding capacity with UA transporters and JAK2 proteins. In summary, apigenin could improve UA metabolism and attenuate renal injury through inhibiting UA production, promoting excretion, and suppressing the JAK2/STAT3 signaling pathway in HUA mice. The results suggest that apigenin may be a suitable drug candidate for management of HUA and its associated renal injury.

1 October 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
BCBeibei Chen
Beibei Chen
JWJunping Wei
Junping Wei
RZRuyuan Zhu
Ruyuan Zhu
HZHao Zhang
Hao Zhang
BXBingke Xia
Bingke Xia
DZDongwei Zhang
Dongwei Zhang

10 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
BXBingke Xia
Bingke Xia
XDXuan Dai
Xuan Dai
HSHanfen Shi
Hanfen Shi
JYJiyuan Yin
Jiyuan Yin
TXTianshu Xu
Tianshu Xu
DZDongwei Zhang
Dongwei Zhang
Recent interest in preventing the development of osteoporosis has focused on the regulation of redox homeostasis. However, the action of lycopene (LYC), a strong natural antioxidant compound, on osteoporotic bone loss remains largely unknown. Here, we show that oral administration of LYC to OVX rats for 12 weeks reduced body weight gain, improved lipid metabolism, and preserved bone quality. In addition, LYC treatment inhibited ROS overgeneration in serum and bone marrow in OVX rats, and in BMSCs upon H2O2 stimulation, leading to inhibiting adipogenesis and promoting osteogenesis during bone remodeling. At the molecular level, LYC improved bone quality via an increase in the expressions of FoxO1 and Runx2 and a decrease in the expressions of PPARγ and C/EBPα in OVX rats and BMSCs. Collectively, these findings suggest that LYC attenuates osteoporotic bone loss through promoting osteogenesis and inhibiting adipogenesis via regulation of the FoxO1/PPARγ pathway driven by oxidative stress, presenting a novel strategy for osteoporosis management.

22 February 2025 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
YZYueyi Zhang
Yueyi Zhang
HSHanfen Shi
Hanfen Shi
XDXuan Dai
Xuan Dai
JSJin Shen
Jin Shen
JYJiyuan Yin
Jiyuan Yin
DZDongwei Zhang
Dongwei Zhang

3 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
BXBingke Xia
Bingke Xia
XDXuan Dai
Xuan Dai
HSHanfen Shi
Hanfen Shi
JYJiyuan Yin
Jiyuan Yin
TXTianshu Xu
Tianshu Xu
DZDongwei Zhang
Dongwei Zhang
Recent interest in preventing the development of osteoporosis has focused on the regulation of redox homeostasis. However, the action of lycopene (LYC), a strong natural antioxidant com-pound, on osteoporotic bone loss remains largely unknown. Here, we show that the administra-tion of LYC to OVX rats reduces body weight gain, improves lipid metabolism and preserves bone quality. In addition, LYC treatment inhibits ROS overgeneration in serum and bone marrow in OVX rats, and in BMSCs upon H2O2 stimulation, leading to inhibiting adipogenesis and pro-moting osteogenesis during bone remodeling. Mechanically, LYC may improve bone quality via an increase in the expressions of FoxO1 and Runx2, and a decrease in the expressions of PPARγ and C/EBPα in OVX rats and BMSCs. Collectively, these findings suggest that LYC attenuates osteoporotic bone loss through promoting osteogenesis and inhibiting adipogenesis via regula-tion of the FoxO1/PPARγ pathway driven by oxidative stress, presenting a novel strategy for os-teoporosis management.

18 January 2026 in Phytomedicine
Verified
Journal Article
Closed access
GYGaiyue Yue
Gaiyue Yue
SWShan Wang
Shan Wang
XDXuan Dai
Xuan Dai
YLYongqi Li
Yongqi Li
KZKun Zhu
Kun Zhu
DZDongwei Zhang
Dongwei Zhang